Although the 2020 numbers will look much different, the 2019 Merritt Hawkins survey – representing 93 hospitals — shows significant increases over prior years in revenue driven for hospitals by a range of specialties, including internal medicine, cardiology, neurosurgery, and gastroenterology. How will the pandemic affect the financial outlook in 2020 and beyond, and where did oncology land?

Getting out and enjoying the sunshine seems to be more important than ever right now, and some studies indicated that not getting enough of vitamin D may be a risk factor for all-cause mortality, and numerous researchers have concluded that we should all probably be getting a little more of it. According to the available research, here are three diseases that vitamin D may help you and your patients combat.

Published in Clinical Advances in Hematology & Oncology, this article presents an overview of the currently available monoclonal antibody treatments in multiple myeloma (MM), discussing  the clinical value, significant potential, and possible limitations of these immunotherapeutic approaches to driving deeper responses and achieving longer overall survival among patients with a challenging disease.

Fifty-seven years ago this month, President John F. Kennedy was in the emergency room of Parkland Memorial Hospital in Dallas. Retired Iowa cardiologist Joe Goldstrich, MD, was the most junior person actively participating in the JFK resuscitation efforts. He spoke with MedPage Today about treating the President, nearly treating his assassin, and his one regret.

This randomized controlled trial was to assess whether recommending surgical mask use outside the home reduces wearers’ risk for SARS-CoV-2 infection in a setting where masks were uncommon and not among recommended public health measures. The results from the study were published in the Annals of Internal Medicine.

In this Q&A, Dr. Gautam Borthakur from the University of Texas MD Anderson Cancer Center talks with Clinical Advances in Hematology & Oncology about the goals, treatment options (including tailored treatment), differences in de novo vs. therapy-related, and other suggestions in patients with core-binding factor acute myeloid leukemia (AML).